JP2017534644A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534644A5 JP2017534644A5 JP2017525007A JP2017525007A JP2017534644A5 JP 2017534644 A5 JP2017534644 A5 JP 2017534644A5 JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017525007 A JP2017525007 A JP 2017525007A JP 2017534644 A5 JP2017534644 A5 JP 2017534644A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 102100034608 Angiopoietin-2 Human genes 0.000 claims 2
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 claims 2
- 101000955962 Homo sapiens Vacuolar protein sorting-associated protein 51 homolog Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000005734 heterodimerization reaction Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192524.8 | 2014-11-10 | ||
| EP14192524 | 2014-11-10 | ||
| PCT/EP2015/075876 WO2016075035A1 (en) | 2014-11-10 | 2015-11-06 | Anti-ang2 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020205947A Division JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534644A JP2017534644A (ja) | 2017-11-24 |
| JP2017534644A5 true JP2017534644A5 (show.php) | 2018-12-06 |
Family
ID=51868115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525007A Pending JP2017534644A (ja) | 2014-11-10 | 2015-11-06 | 抗ａｎｇ２抗体及び使用方法 |
| JP2020205947A Pending JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020205947A Pending JP2021050229A (ja) | 2014-11-10 | 2020-12-11 | 抗ａｎｇ２抗体及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10538585B2 (show.php) |
| EP (1) | EP3218398A1 (show.php) |
| JP (2) | JP2017534644A (show.php) |
| KR (1) | KR20170082594A (show.php) |
| CN (1) | CN107001456A (show.php) |
| AR (1) | AR102595A1 (show.php) |
| AU (1) | AU2015345321A1 (show.php) |
| BR (1) | BR112017009790A2 (show.php) |
| CA (1) | CA2963606A1 (show.php) |
| IL (1) | IL251477A0 (show.php) |
| MX (1) | MX2017005642A (show.php) |
| SG (1) | SG11201703458UA (show.php) |
| TW (1) | TW201630935A (show.php) |
| WO (1) | WO2016075035A1 (show.php) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2537100T3 (es) | 2009-04-07 | 2015-06-02 | Roche Glycart Ag | Anticuerpos biespecíficos trivalentes |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| JP2017537896A (ja) | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| JP7074859B2 (ja) * | 2017-12-22 | 2022-05-24 | エフ．ホフマン－ラ ロシュ アーゲー | 疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法 |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| EP4183802A4 (en) | 2020-06-22 | 2024-11-06 | Innovent Biologics (Suzhou) Co., Ltd. | ANTI-ANG-2 ANTIBODY AND ITS USE |
| JP2023536499A (ja) * | 2020-08-07 | 2023-08-25 | ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド | ヒトアンジオポエチン－２に対する抗体及びその使用 |
| KR20220022878A (ko) * | 2020-08-19 | 2022-02-28 | 주식회사 파멥신 | 변형 항체 및 이의 제조방법 |
| CN115772544B (zh) * | 2021-09-06 | 2024-04-26 | 合肥星眸生物科技有限公司 | 抗vegf-a和ang-2的aav载体 |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| CN117820490A (zh) * | 2022-09-28 | 2024-04-05 | 科兴生物制药股份有限公司 | Vegf和ang-2双特异性抗体及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935343A (en) | 1986-08-08 | 1990-06-19 | Syntex (U.S.A.) Inc. | Monoclonal antibodies for interleukin-1β |
| GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| AU2003208946A1 (en) | 2002-02-28 | 2003-09-16 | Eli Lilly And Company | Anti-interleukin-1 beta analogs |
| EP1517921B1 (en) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
| EP1590369B1 (en) | 2003-01-24 | 2016-03-16 | Applied Molecular Evolution, Inc. | Human il-1 beta antagonists |
| US20050282233A1 (en) | 2004-03-05 | 2005-12-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for VEGF/PDGF family of growth factors |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| AU2008247382B2 (en) | 2007-05-07 | 2014-06-05 | Medimmune, Llc | Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JO2913B1 (en) * | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| EP2293816B1 (en) | 2008-06-06 | 2012-11-07 | XOMA Technology Ltd. | Methods for the treatment of rheumatoid arthritis |
| RU2368359C1 (ru) | 2008-07-22 | 2009-09-27 | Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) | Способ лечения возрастной макулярной дегенерации |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| BR112013003279A2 (pt) | 2010-08-13 | 2016-06-14 | Genentech In | “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal” |
| WO2012034039A2 (en) | 2010-09-10 | 2012-03-15 | Apexigen, Inc. | Anti-il-1 beta antibodies and methods of use |
| MX348071B (es) * | 2011-03-16 | 2017-05-26 | Amgen Inc | Variantes de fc. |
| EP2726088B1 (en) * | 2011-06-29 | 2019-01-02 | Amgen Inc. | Predictive biomarker of survival in the treatment of renal cell carcinoma |
| SG11201408196RA (en) | 2012-06-28 | 2015-03-30 | Molecular Partners Ag | Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| EA032192B1 (ru) * | 2012-07-13 | 2019-04-30 | Роше Гликарт Аг | Биспецифическое антитело к vegf/ang-2, нуклеиновая кислота, кодирующая это антитело, вектор, содержащий нуклеиновую кислоту, клетка-хозяин, способ получения биспецифического антитела и содержащая его фармацевтическая композиция |
| WO2014049100A1 (en) * | 2012-09-28 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents |
| BR112015006363A2 (pt) * | 2012-09-28 | 2017-08-08 | Boehringer Ingelheim Int | combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r |
| SG11201503637SA (en) | 2012-11-08 | 2015-06-29 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects |
| HK1216428A1 (zh) | 2012-11-09 | 2016-11-11 | 辉瑞公司 | 血小板衍生生长因子b之特异性抗体及其组合物和用途 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| TWI747803B (zh) * | 2013-04-29 | 2021-12-01 | 瑞士商赫孚孟拉羅股份公司 | 人類結合ｆｃｒｎ之經修飾抗體及使用方法 |
| CA2923591A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
| MX382848B (es) * | 2014-01-15 | 2025-03-13 | Hoffmann La Roche | Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas. |
| AU2015345322A1 (en) | 2014-11-10 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-PDGF-B antibodies and methods of use |
| JP2017537896A (ja) * | 2014-11-10 | 2017-12-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重特異性抗体及び眼科に使用する方法 |
| EP3218402A1 (en) | 2014-11-10 | 2017-09-20 | F. Hoffmann-La Roche AG | Anti-il-1beta antibodies and methods of use |
| WO2016209972A1 (en) * | 2015-06-26 | 2016-12-29 | Amgen Inc. | Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor |
| MX2019014199A (es) * | 2017-06-02 | 2020-01-23 | Boehringer Ingelheim Int | Tratamiento de combinacion antineoplasico. |
-
2015
- 2015-11-06 BR BR112017009790A patent/BR112017009790A2/pt not_active Application Discontinuation
- 2015-11-06 CA CA2963606A patent/CA2963606A1/en not_active Abandoned
- 2015-11-06 AU AU2015345321A patent/AU2015345321A1/en not_active Abandoned
- 2015-11-06 SG SG11201703458UA patent/SG11201703458UA/en unknown
- 2015-11-06 MX MX2017005642A patent/MX2017005642A/es unknown
- 2015-11-06 KR KR1020177015610A patent/KR20170082594A/ko not_active Withdrawn
- 2015-11-06 CN CN201580060787.3A patent/CN107001456A/zh active Pending
- 2015-11-06 WO PCT/EP2015/075876 patent/WO2016075035A1/en not_active Ceased
- 2015-11-06 JP JP2017525007A patent/JP2017534644A/ja active Pending
- 2015-11-06 EP EP15790575.3A patent/EP3218398A1/en not_active Withdrawn
- 2015-11-09 AR ARP150103648A patent/AR102595A1/es unknown
- 2015-11-09 TW TW104136927A patent/TW201630935A/zh unknown
-
2017
- 2017-03-30 IL IL251477A patent/IL251477A0/en unknown
- 2017-05-10 US US15/591,600 patent/US10538585B2/en not_active Expired - Fee Related
-
2020
- 2020-12-11 JP JP2020205947A patent/JP2021050229A/ja active Pending